37 active not recruiting, 36 completed, 14 recruiting, 14 terminated. 111 Phase 2, 26 Phase 1.
Follow Refractory Multiple Myeloma: new trials by email Literature Review of Refractory Multiple Myeloma trials Research Report on Refractory Multiple Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse Biospecimen Collection, Bone Marrow Biopsy, Carfilzomib - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 80 | 2027-05-22 | 2026-10-28 |
| Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 162 | 2027-04-12 | 2026-10-16 |
| Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Cytokine Release Syndrome, Recurrent Multiple Myeloma | Phase 2 | Recruiting | Naresh Bumma | 35 | 2026-07-17 | 2026-10-06 |
| Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma Selinexor, Carfilzomib, Isatuximab - Relapse Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Natalie Callander | 62 | 2026-05-21 | 2026-08-31 |
| Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma Linvoseltamab, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 30 | 2026-03-24 | 2026-09-16 |
| Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Recruiting | Mayo Clinic | 44 | 2025-09-18 | 2026-08-26 |
| Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease Mezigdomide, Carfilzomib, Dexamethasone - Extramedullary Disease in Multiple Myeloma, Recurrent Multiple Myeloma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 28 | 2025-05-01 | 2026-08-18 |
| Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma Iberdomide, Belantamab Mafodotin, Dexamethasone - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Suspended | Alliance for Clinical Trials in Oncology | 88 | 2025-04-23 | 2026-10-02 |
| Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma Elranatamab injection - Refractory Multiple Myeloma | Phase 2 | Recruiting | Ontario Clinical Oncology Group (OCOG) | 40 | 2025-03-28 | 2026-09-28 |
| Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM Siltuximab, Teclistamab(FDA-approved) - Multiple Myeloma, Cytokine Release Syndrome | Phase 2 | Withdrawn | Jack Khouri, MD | 2025-01-01 | 2025-03-03 | |
| MMRC Horizon One: RRMM (MMRC-099) Teclistamab Monotherapy, Teclistamab - Relapse Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Active not recruiting | Multiple Myeloma Research Consortium | 300 | 2024-11-17 | 2026-06-05 |
| Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM Elotuzumab, Iberdomide, Dexamethasone - Myeloma, Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Omar Nadeem, MD | 49 | 2024-11-01 | 2026-10-07 |
| Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma Isatuximab, Belantamab mafodotin, Pomalidomide - Relapsed Cancer, Refractory Multiple Myeloma | Phase 2 | Recruiting | Massachusetts General Hospital | 50 | 2024-05-31 | 2026-01-14 |
| Elranatamab in R/R Multiple Myeloma Elranatamab - Refractory Multiple Myeloma, Relapse Multiple Myeloma | Phase 2 | Recruiting | Massachusetts General Hospital | 32 | 2024-03-08 | 2026-08-31 |
| Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma Iberdomide, Carfilzomib, Daratumumab - Refractory Multiple Myeloma, Relapsed Multiple Myeloma | Phase 2 | Recruiting | Benjamin T Diamond, MD | 30 | 2024-02-20 | 2026-03-11 |
| Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma Belantamab Mafodotin, Biospecimen Collection, Bone Marrow Aspirate - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Recruiting | Mayo Clinic | 62 | 2024-01-04 | 2026-07-14 |
| IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers IDP-023, Rituximab, Daratumumab - NHL, Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Indapta Therapeutics, INC. | 128 | 2023-10-25 | 2025-06-03 |
| Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma Belantamab mafodotin - Refractory Multiple Myeloma, Relapse Multiple Myeloma | Phase 2 | Terminated | Medical College of Wisconsin | 1 | 2022-07-19 | 2025-01-28 |
| Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma Bone Marrow Biopsy, Dexamethasone, Lenalidomide - Multiple Myeloma, Recurrent Multiple Myeloma | Phase 2 | Terminated | Mayo Clinic | 17 | 2022-06-15 | 2026-09-28 |
| Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma Elotuzumab, Selinexor, and Dexamethasone (ESd) - Relapsed Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Withdrawn | Tulane University School of Medicine | 2022-04-27 | 2022-05-04 |
Showing 20 of 111. Sign in to see all of them.
Multiple Myeloma (111) · Lymphoma (31) · Hematologic Neoplasms (20) · Recurrence (16) · Hodgkin Disease (14) · Leukemia, Lymphocytic, Chronic, B-Cell (14) · Lymphoma, B-Cell, Marginal Zone (14) · Lymphoma, Follicular (14) · Lymphoma, Non-Hodgkin (14) · Lymphoma, T-Cell, Cutaneous (14) · Mycosis Fungoides (14) · Sezary Syndrome (14) · Waldenstrom Macroglobulinemia (14) · Immunoblastic Lymphadenopathy (13) · Lymphoma, Extranodal NK-T-Cell (13)
Hemic and Lymphatic Diseases (111) · Blood Protein Disorders (110) · Cardiovascular Diseases (110) · Hematologic Diseases (110) · Hemorrhagic Disorders (110) · Hemostatic Disorders (110) · Immune System Diseases (110) · Immunoproliferative Disorders (110) · Lymphoproliferative Disorders (110) · Neoplasms (110) · Neoplasms by Histologic Type (110) · Vascular Diseases (110) · Paraproteinemias (109) · Neoplasms, Plasma Cell (108) · Lymphatic Diseases (47)
Dexamethasone (32) · Biopsy (24) · Specimen Handling (22) · Magnetic Resonance Spectroscopy (20) · Calcium Dobesilate (17) · pomalidomide (13) · Cyclophosphamide (12) · Peripheral Blood Stem Cell Transplantation (12) · Whole-Body Irradiation (12) · carfilzomib (12) · Mycophenolic Acid (11) · fludarabine phosphate (11) · Bortezomib (10) · Cyclosporine (7) · Tacrolimus (7)
National Cancer Institute (NCI) (43) · Fred Hutchinson Cancer Center (12) · Mayo Clinic (11) · University of Washington (3) · Andrew Yee, MD (2) · Case Comprehensive Cancer Center (2) · Massachusetts General Hospital (2) · Roswell Park Cancer Institute (2) · Weill Medical College of Cornell University (2) · Ajai Chari (1) · Alliance for Clinical Trials in Oncology (1) · Attaya Suvannasankha (1) · Barbara Ann Karmanos Cancer Institute (1) · Benjamin T Diamond, MD (1) · City of Hope Medical Center (1)
United States (97) · Italy (7) · China (3) · Germany (3) · Canada (1) · Guam (1) · Israel (1) · Mexico (1) · Puerto Rico (1) · Singapore (1) · Spain (1) · Switzerland (1) · Taiwan (1)
Shaji Kumar (4) · Brenda Sandmaier (3) · David Maloney (3) · David S Hong (3) · Filip Janku (3) · Andrew Yee, MD (2) · Jason J Luke (2) · John L Hays (2) · Joseph R. Mikhael, M.D. (2) · Kevin M Kalinsky (2) · Leona Holmberg (2) · Shaji K. Kumar, M.D. (2) · Shaji Kumar, M.D. (2) · Vivek Roy, M.D. (2) · Aaron S Mansfield (1)
PMID 32499241, PMID 19182205, PMID 19900571, PMID 23927993, PMID 23950178, PMID 24241210, PMID 25395429, PMID 26331432, PMID 26586415, PMID 28148715, PMID 28684537, PMID 31433920, PMID 32463741, PMID 33048619, PMID 35133871, PMID 35138919, PMID 36351402, PMID 37053535, PMID 37322121, PMID 37934000, PMID 38591867, PMID 39666929, PMID 39693587, PMID 39913886, PMID 40153687, PMID 40865033, PMID 41066729, PMID 41533998, PMID 41556942, PMID 42719971
U10CA180820 (33), U24CA196172 (17), P30CA015704 (7), N01CM62205 (3), P01CA018029 (3), P01CA078902 (3), P30CA015083 (3), 2019 (1), N01CM00039 (1), N01CM00070 (1), N01CM17104 (1), N01CM62203 (1), N01CM62207 (1), N01CM62208 (1), P30CA016058 (1)